3 Defensive Stocks to Buy as the AI Selloff Rattles Wall Street The recent AI sell-off shows why diversification matters. Here are three stocks that can help investors diversify their portfolios. Barchart · Oct 23
HRSA Names 10 Drugmakers and 21 Drugs for 340B Rebate Pilot as Hospitals Weigh Options Before January Launch HRSA approved 10 drugmakers and 21 drugs, including Eliquis and Jardiance, for its 340B rebate pilot starting Jan. 1 as hospitals weigh legal options. Medical Daily · Oct 5
Pfizer and the $200 Billion-Dollar Cardiovascular Market Pfizer's cardiovascular business highlights the intersection of drug pricing, marketing, patents, and competition in the rapidly growing $200 billion heart disease market. International Business Times · Jul 23
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday. Benzinga · Jul 17, 2025
Bristol Myers Q1 Earnings Surpass Street Expectations, Lowers FY22 Guidance Bristol-Myers Squibb Co (NYSE:BMY) has posted Q1 revenues of $11.65 billion, an increase of 5% Y/Y (7% constant currency), beating the consensus of $11.36 billion. Eliquis, Opdivo, cell therapy products, and Reblozyl drove sales growth. Eliquis sales increased 11% to $3.21 billion, Opdivo sales increased 12% to $1.92 billion, and Yervoy sales… Benzinga · Apr 29, 2022